China Capecitabine Market Analysis and Forecast, 2016-2020 and 2021-2025

DUBLIN, December 31, 2021 / PRNewswire / – The “Investigation Report on from China Capecitabine Market 2021-2025 report “has been added to ResearchAndMarkets.com offer.

Capecitabine is a pyrimidine analog (pentoxycarbonyl-deoxy-cytosine nucleoside) that has anti-tumor activity to inhibit a variety of solid tumors, including breast and colon cancer. Capecitabine was developed by Roche. Its product, XELODA was approved to enter the Chinese market in 2001. By 2020, there are several manufacturers in the capecitabine market in China.

According to the market research, sales of capecitabine in the Chinese market increased year on year from 2016 to 2019. Due to the impact of the COVID-19 pandemic on all diagnostic and medical services. hospital treatment, sales in 2020 declined to CNY 914 million, a decrease of 9.31% year-on-year. The sales CAGR of capecitabine in the Chinese market from 2016 to 2020 is 1.21%.

The analyst expects that with the mitigation of the COVID-19 pandemic, sales of capecitabine in the Chinese market will experience restorative growth in 2021-2025. In 2020, the number of COVID-19 breast cancers worldwide reached 2.26 million and the number of colon cancers reached 1.93 million, both on the rise.

The number of breast and colon cancers in China will also be on the rise in the future. Therefore, the sales volume of capecitabine, which is used to inhibit the anti-tumor activity of a variety of solid tumors, will increase as the number of breast and colon cancer patients increases. China.

There is also room for sales to increase. In addition, by the end of 2020, a number of companies led by Chengdu Yuandong Biopharmaceuticals have already applied for approval of a generic drug for capecitabine. Over the next few years, more and more manufacturers will join the Chinese market. The sales volume and sales of capecitabine in China should increase.

Topics covered:

  • The impact of COVID-19 on from China Capecitabine market
  • Sales value of from China Capecitabine 2016-2020
  • competitive landscape of from China Capecitabine market
  • Capecitabine price in China
  • Capecitabine price in China by regions and manufacturers
  • Analysis of factors affecting the development of from China Capecitabine market
  • Perspective of from China Capecitabine market from 2021 to 2025

Main topics covered:

1 Relevant concepts of capecitabine
1.1 Indications for capecitabine
1.2 History of the development of capecitabine in China
1.3 Approval information for capecitabine in China
1.4 The impact of COVID-19 on sales of capecitabine in China

2 Sales of capecitabine in China, 2016-2020
2.1 Capecitabine sales value
2.1.1 Overall value of sales
2.1.2 Sales value by region
2.2 Capecitabine sales volume
2.2.1 Global sales volume
2.2.2 Sales Volume by Region
2.3 Sales of Capecitabine by Dosage Form in China, 2016-2020
2.3.1 Tablets
2.3.2 Analysis of other dosage forms

3 Major Manufacturers Analysis of Capecitabine in China, 2016-2020
3.1 Major Manufacturers of Capecitabine Market Share Analysis
3.1.1 Market share by sales value
3.1.2 Market share by sales volume
3.2 Shanghai Roche Pharmaceuticals Co., Ltd.
3.2.1 Company profile
3.2.2 Sales of XELODA (Capecitabine from Shanghai Roche Pharmaceuticals Co., Ltd.) in China
3.3 Jiangsu Heng Rui Pharmaceutical Co., Ltd.
3.3.1 Company profile
3.3.2 Sales of Aibin (Capecitabine by Jiangsu Hengrui Medicine Co,. Ltd.) in China
3.4 Qilu Pharmaceutical Co., Ltd.
3.4.1 Company profile
3.4.2 Sales of Zuolun (Capecitabine by Qilu Pharmaceutical Co., Ltd.) in China
3.5 Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
3.5.1 Company Profile
3.5.2 Sales of Shoufu (Capecitabine by Chia Tai Tianqing Pharmaceutical Group Co., Ltd.) in China
3.6 Hoffmann-La Roche inc
3.6.1 Company Profile
3.6.2 Sales of XELODA (Capecitabine from Hoffmann-La Roche Inc) in China

4 Price of capecitabine from different manufacturers in China, 2020-2021
4.1 Shanghai Roche Pharmaceuticals Co., Ltd. (XELODA)
4.2 Jiangsu Hengrui Medicine Co, Ltd. (Aibine)
4.3 Qilu Pharmaceutical Co., Ltd. (Zuolun)
4.4 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Shoufu)
4.5 Hoffmann-La Roche Inc (XELODA)

5 China Capecitabine Drug Market Outlook, 2021-2025
5.1 Factors influencing the development of the Chinese capecitabine market
5.1.1 The impact of COVID-19 on the Chinese capecitabine market
5.1.2 Market Drivers and Opportunities
5.1.3 Market threats and challenges
5.2 Market Size Forecast
5.3 Market Trend Forecast

Companies mentioned

  • Shanghai Roche Pharmaceuticals Co., Ltd. (XELODA)
  • Jiangsu Hengrui Medicine Co, Ltd. (Aibine)
  • Qilu Pharmaceutical Co., Ltd. (Zuolun)
  • Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (Shoufu)
  • Hoffmann-La Roche Inc (XELODA)

For more information on this report, visit https://www.researchandmarkets.com/r/u2r8ax

Media contact:

Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1904
Fax (outside the United States): + 353-1-481-1716

SOURCE Research and Markets

Related links

http://www.researchandmarkets.com


Source link

Comments are closed.